Glutamine-addiction in cisplatin resistant cancer cells is mediated by SLC7A11 and can be targeted with asparaginase therapy
J. Wang, R. Strauss, J. Bartek, S. G. Rudd
This study identifies SLC7A11 as a mediator of cisplatin resistance in cancer cells and shows asparaginase therapy can target this resistance.
bioRxiv · Jul 19, 2024 · PreprintCancer Biology